Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Causal Effects of Lifetime Smoking on Breast and Colorectal Cancer Risk: Mendelian Randomization Study
Dimou, Niki , Bouras, Emmanouil , Tsilidis, Konstantinos K. , Martin, Richard M. , Gram, Inger Torhild , Bakker, Marije F. , Brenner, Hermann , Figueiredo, Jane C. , Fortner, Renée T. , Gruber, Stephen B. , Guelpen, Bethany Van , Lindor, Noralane M. , Sánchez, María‐José , Tindle, Hilary A. , Weiderpass, Elisabete , Gunter, Marc J. , Murphy, Neil , Martin, Richard M , Gram, Inger T , Brenner, Hermann , Fortner, Renée T , Gruber, Stephen B , Van Guelpen, Bethany , Hsu, Li , Kaaks, Rudolf , Kweon, Sun-Seog , Severi, Gianluca , Tumino, Rosario , Weiderpass, Elisabete , Gunter, Marc J , Murphy, Neil , Dimou, Niki , Tsilidis, Konstantinos K , Bouras, Emmanouil , Sánchez, Maria-Jose , Yarmolinsky, James , Lewis, Sarah J. , Kaaks, Rudolf , Lin, Yi , Newcomb, Polly A. , Severi, Gianluca , ­Tumino, ­Rosario

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 2, 2021 | Volume: 30 | Issue: 5 | Pages: 953-964

10.1158/1055-9965.epi-20-1218 | PMID 33653810 Get It

Abstract Background: Observational evidence has shown that smoking is a risk factor for breast and colorectal cancer. We used Mendelian randomization (MR) to examine causal associations between smoking and risks of breast and colorectal cancer. Methods: Genome-Wide Association Study summary data were used to identify genetic variants associated with lifetime amount of smoking (n = 126 variants) and ever having smoked regularly (n = 112 variants). Using two-sample MR, we examined these variants in relation to incident breast (122,977 cases/105,974 controls) and colorectal cancer (52,775 cases/45,940 controls). Results: In inverse-variance weighted models, a genetic predisposition to higher lifetime amount of smoking was positively associated with breast cancer risk [OR per 1-SD increment: 1.13; 95% confidence interval (CI): 1.00–1.26; P = 0.04]; although heterogeneity was observed. Similar associations were found for estrogen receptor–positive and estrogen receptor–negative tumors. Higher lifetime amount of smoking was positively associated with colorectal cancer (OR per 1-SD increment, 1.21; 95% CI, 1.04–1.40; P = 0.01), colon cancer (OR, 1.31; 95% CI, 1.11–1.55; P < 0.01), and rectal cancer (OR, 1.36; 95% CI, 1.07–1.73; P = 0.01). Ever having smoked regularly was not associated with risks of breast (OR, 1.01; 95% CI, 0.90–1.14; P = 0.85) or colorectal cancer (OR, 0.97; 95% CI, 0.86–1.10; P = 0.68). Conclusions: These findings are consistent with prior observational evidence and support a causal role of higher lifetime smoking amount in the development of breast and colorectal cancer. Impact: The results from this comprehensive MR analysis indicate that lifetime smoking is a causal risk factor for these common malignancies.
Survival outcomes in locally advanced cutaneous squamous cell carcinoma presenting with clinical perineural invasion alone
Hazim, Antonious , Reed, Clay T. , Price, Katharine A. , Foote, Robert L. , Neben-Wittich, M.A. , Jenkins, Sarah M. , Hazim, Antonious Z , Neben-Wittich, Michelle, DeLone, David R. , Daniel, J. , Smith, Carin Y. , Chintakuntlawar, Ashish V.

Mayo Clinic

Head & Neck | March 1, 2021 | Volume: 43 | Issue: 7 | Pages: 1995-2001

10.1002/hed.26661 | PMID 33644935 Get It

AbstractBackgroundCutaneous squamous cell carcinomas (CSCC) involving the head and neck are common, but initial presentation or recurrence limited to the cranial nerves is rare.MethodsWe conducted a retrospective study of 21 patients with clinical perineural invasion (PNI) from CSCC and no measurable disease by RECIST 1.1. Patients treated with radiotherapy or chemoradiotherapy were included.ResultsThe median time from symptom onset until diagnosis was 13.0 months (2.6–83.1). All patients received radiotherapy. Fourteen received concurrent systemic therapy. The median follow‐up time was 30.5 months (1.1–106.0). Ten patients recurred, with the majority being locoregional. The 2‐year overall survival rate was 85%. The median progression‐free survival (PFS) was 21.5 months with an estimated 2‐year PFS of 44.5% (95%CI: 22.3–66.8).ConclusionsCSCCs with clinical PNI alone are difficult to diagnose and can have a long interval between appearance of symptoms and diagnosis. They can successfully be treated with chemoradiotherapy. However, many patients still suffer from locoregional recurrences.
NGLY1 Deficiency: A Rare Newly Described Condition with a Typical Presentation
Dabaj, Ivana , Sudrié‐Arnaud, Bénédicte , Lecoquierre, François , Raymond, Kimiyo , Ducatez, Franklin , Guerrot, Anne‐Marie , Snanoudj, Sarah , Coutant, Sophie , Saugier-Véber, Pascale , Marret, Stéphane , Tebani, Abdellah , Bekri, Soumeya , Bekri, Soumeya , Lecoquierre, Francois , Dabaj, Ivana , Nicolas, Gaël

Mayo Clinic

Life | February 27, 2021 | Volume: 11 | Issue: 3 | Pages: 187

10.3390/life11030187 | PMID 33673403 Get It

NGLY1 deficiency is the first recognized autosomal recessive disorder of N-linked deglycosylation (NGLY1-CDDG). This severe multisystemic disease is still poorly known and, to date, most cases have been diagnosed through whole exome or genome sequencing. The aim of this study is to provide the clinical, biochemical and molecular description of the first NGLY1-CDDG patient from France along with a literature review. The index case presented with developmental delay, acquired microcephaly, hypotonia, alacrimia, feeding difficulty, and dysmorphic features. Given the complex clinical picture and the multisystemic involvement, a trio-based exome sequencing was conducted and urine oligosaccharides were assessed using mass spectrometry. The exome sequencing revealed a novel variant in the NGLY1 gene in a homozygous state. NGLY1 deficiency was confirmed by the identification of the Neu5Ac1Hex1GlcNAc1-Asn oligosaccharide in the urine of the patient. Literature review revealed the association of some key clinical and biological features such as global developmental delay—hypertransaminasemia, movement disorders, feeding difficulties and alacrima/hypolacrima.
Use of a Rigid Bronchoscope as the Sole Prebypass Airway During Pediatric Tracheal Tumor Resection: A Case Report
Evans, Michael A. , Stephens, Elizabeth H. , Chun, Yeona , Backer, Carl L., Lavin, Jennifer M. , Maurrasse, Sarah E.

Mayo Clinic

A&A Practice | February 27, 2021 | Volume: 15 | Issue: 2 | Pages: e01399

10.1213/xaa.0000000000001399 | PMID 33784445 Get It

We describe the anesthetic and operative techniques utilized for a tracheal tumor resection in a pediatric patient with 95% tracheal occlusion. In prior tracheal tumor cases that dictated complete resection, our team had been able to comfortably bypass a tumor with an endotracheal tube. In this case, we could not intubate past the tumor. A rigid bronchoscope was able to be placed past the tumor, so we continued with sternotomy and dissection before cardiopulmonary bypass while ventilating through that bronchoscope as our definitive airway.
Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity
Eschbacher, Kathryn L. , Alvi, Mohammed Ali , Jenkins, Sarah M. , Ruff, Michael W. , Kerezoudis, Panagiotis , Neth, Bryan J. , Pasion, Romela, Kizilbash, Sani H. , Neth, Byran J. , Kizilbash, Sani H , Alvi, Mohammed Ali , Ida, Cristiane M. , Johnson, Derek R. , Daniels, David J. , Raghunathan, Aditya

Mayo Clinic

American Journal of Surgical Pathology | February 26, 2021 | Volume: 45 | Issue: 8 | Pages: 1082-1090

10.1097/pas.0000000000001690 | PMID 33606385 Get It

Posterior fossa (PF) diffuse gliomas in pediatric patients frequently harbor the H3 K27M mutation. Among adults, PF diffuse gliomas are rare, with limited data regarding molecular features and clinical outcomes. We identified 28 adult PF diffuse glioma patients (17 males; median: 50 y, range: 19 to 78 y), with surgery performed at our institution (13 brainstem; 15 cerebellum). Histologic subtypes included anaplastic astrocytoma (n=21), glioblastoma (n=6), and diffuse astrocytoma (n=1). Immunohistochemistry was performed for H3 K27M (n=26), IDH1-R132H (n=28), and ATRX (n=28). A 150-gene neuro-oncology-targeted next-generation sequencing panel was attempted in 24/28, with sufficient informative material in 15 (51.7%). Tumors comprised 4 distinct groups: driver mutations in H3F3A (brainstem=4; cerebellum=2), IDH1 (brainstem=4; cerebellum=4), TERT promotor mutation (brainstem=0; cerebellum=3), and none of these (n=5), with the latter harboring mutations of TP53 , PDGFRA , ATRX , NF1 , and RB1 . All TERT promoter–mutant cases were IDH-wild-type and arose within the cerebellum. To date, 20 patients have died of disease, with a median survival of 16.3 months, 1-year survival of 67.5%. Median survival within the subgroups included: H3F3A =16.4 months, IDH mutant=113.4 months, and TERT promoter mutant=12.9 months. These findings suggest that PF diffuse gliomas affecting adults show molecular heterogeneity, which may be associated with patient outcomes and possible response to therapy, and supports the utility of molecular testing in these tumors.
Use of bioimpedance spectroscopy for prospective surveillance and early diagnosis of breast cancer–related lymphedema
Forte, Antonio J. , Huayllani, María T. , Kassis, Salam Al, Ciudad, Pedro , Lu, Xiaona , Moore, Pamela A., McLaughlin, Sarah A. , Boczar, Daniel , Ávila, Francisco R. , Forte, Antonio Jorge

Mayo Clinic

Breast Disease | February 26, 2021 | Volume: 40 | Issue: 2 | Pages: 85-93

10.3233/bd-201008 | PMID 33646139 Get It

BACKGROUND: Bioimpedance spectroscopy has been suggested as a useful tool for early diagnosis of breast cancer–related lymphedema (BCRL). We aimed to describe the outcomes of published studies that evaluated bioimpedance analysis as a method for prospective surveillance and early diagnosis of BCRL. METHODS: We queried the PubMed, Ovid Medline, and EMBASE databases to identify studies that evaluated use of bioimpedance spectroscopy as a diagnostic tool. We used the keywords “bioimpedance” AND (“lymphedema” OR “lymphoedema”) in the search. Only English-language studies that reported quantitative outcomes for patients with BCRL were included. RESULTS: Of 152, 235 and 116 identified articles in PubMed, Ovid Medline and EMBASE databases, only 22 were included. Use of bioimpedance analysis for prospective surveillance has been shown to prevent chronic BCRL. All the cross-sectional and retrospective studies that evaluated bioimpedance for diagnosis of BCRL reported significantly different L-Dex scores between lymphedema patients and healthy participants; in addition, bioimpedance scores were positively correlated with volume of lymphedema. CONCLUSION: Bioimpedance analysis is a potential tool with demonstrated benefits for prevention of chronic BCRL and may be an economic and great alternative for early diagnosis of BCRL.
Association of Social Determinants of Health with Time to Diagnosis and Treatment Outcomes in Idiopathic Subglottic Stenosis
Lee, Jaclyn , Huang, Li‐Ching , Berry, Lynn D., Anderson, Catherine , Amin, Milan R. , Benninger, Michael S. , Blumin, Joel H. , Bock, Jonathan M. , Bryson, Paul C. , Castellanos, Paul F., Chen, Sheau‐Chiann , Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fink, Daniel S. , Franco, Ramon A. , Garrett, C. Gaelyn , Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Hussain, Lena K., Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Lowery, Anne S. , Makani, Samir, Maldonado, Fabien , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , O’Dell, Karla , Ongkasuwan, Julina , Postma, Gregory N. , Reder, Lindsay , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Daele, Douglas J. Van , Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Cohen, Seth M , Dailey, Seth H , Hoffman, Henry T , Lott, David G , Mori, Matthew , Ongkasuwan, Julian , Richardson, Brent E , Gelbard, Alexander , Chen, Sheau-Chiann , Weissbrod, Philip A , Clary, Matthew S. , Guardiani, Elizabeth , Hillel, Alexander T. , Lott, David G. , Mannion, Kyle , Netterville, James L. , Rohde, Sarah L. , Weinberger, Paul , Gelbard, Alexander , Amin, Milan R

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | February 25, 2021 | Volume: 130 | Issue: 10 | Pages: 1116-1124

10.1177/0003489421995283 | PMID 33629608 Get It

Objectives: To examine whether social determinants of health (SDH) factors are associated with time to diagnosis, treatment selection, and time to recurrent surgical intervention in idiopathic subglottic stenosis (iSGS) patients. Methods: Adult patients with diagnosed iSGS were recruited prospectively (2015-2017) via clinical providers as part of the North American Airway Collaborative (NoAAC) and via an online iSGS support community on Facebook. Patient-specific SDH factors included highest educational attainment (self-reported), median household income (matched from home zip code via U.S. Census data), and number of close friends (self-reported) as a measure of social support. Main outcomes of interest were time to disease diagnosis (years from symptom onset), treatment selection (endoscopic dilation [ED] vs cricotracheal resection [CTR] vs endoscopic resection with adjuvant medical therapy [ERMT]), and time to recurrent surgical intervention (number of days from initial surgical procedure) as a surrogate for disease recurrence. Results: The total 810 participants were 98.5% female, 97.2% Caucasian, and had a median age of 50 years (IQR, 43-58). The cohort had a median household income of $62 307 (IQR, $50 345-$79 773), a median of 7 close friends (IQR, 4-10), and 64.7% of patients completed college or graduate school. Education, income, and number of friends were not associated with time to diagnosis via multivariable linear regression modeling. Univariable multinominal logistic regression demonstrated an association between education and income for selecting ED versus ERMT, but no associations were noted for CTR. No associations were noted for time to recurrent surgical procedure via Kaplan Meier modeling and Cox proportional hazards regression. Conclusions: Patient education, income, and social support were not associated with time to diagnosis or time to disease recurrence. This suggests additional patient, procedure, or disease-specific factors contribute to the observed variations in iSGS surgical outcomes.
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Nowakowski, Grzegorz S. , Chiappella, Annalisa , Gascoyne, Randy D. , Scott, David W. , Zhang, Qingyuan , Jurczak, Wojciech , Özcan, Muhıt , Hong, Xiaonan, Zhu, Jun , Jin, Jie , Bergua, Juan , Piazza, Francesco , Móciková, Heidi , Molinari, Anna Lia, Yoon, Dok Hyun , Tani, Monica , Kato, Koji , Czuczman, Myron S., Hersey, Sarah, Kilcoyne, Adrian , Russo, Jacqueline, Hudak, Krista, Zhang, Jingshan , Wade, Steve, Vitolo, Umberto , Song, Yuqin , Bergua, Juan Miguel , Piazza, Francesco , Yamamoto, Kazuhito , Witzig, T.E. , Vitolo, Umberto , Scott, David W , Jurczak, Wojciech , Belada, David , Cavallo, Federica , Izutsu, Koji , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2021 | Volume: 39 | Issue: 12 | Pages: 1317-1328

10.1200/jco.20.01366 | PMID 33621109 Get It

PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent lenalidomide to R-CHOP improved outcomes in ABC-type DLBCL. The goal of the global, phase III ROBUST study was to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL. METHODS Histology and cell-of-origin type were prospectively analyzed by central pathology prior to random assignment and study treatment. Patients with ABC-DLBCL received lenalidomide oral 15 mg/d, days 1-14/21 plus standard R-CHOP21 versus placebo/R-CHOP21 for six cycles. The primary end point was progression-free survival (PFS) per independent central radiology review. RESULTS A total of 570 patients with ABC-DLBCL (n = 285 per arm) were stratified by International Prognostic Index score, age, and bulky disease, and randomly assigned to R2-CHOP or placebo/R-CHOP. Baseline demographics were similar between arms. Most patients completed six cycles of treatment: 74% R2-CHOP and 84% placebo/R-CHOP. The most common grade 3/4 adverse events for R2-CHOP versus placebo/R-CHOP were neutropenia (60% v 48%), anemia (22% v 14%), thrombocytopenia (17% v 11%), and leukopenia (14% v 15%). The primary end point of PFS was not met, with a hazard ratio of 0.85 (95% CI, 0.63 to 1.14) and P = .29; median PFS has not been reached for either arm. PFS trends favoring R2-CHOP over placebo/R-CHOP were seen in patients with higher-risk disease. CONCLUSION ROBUST is the first DLBCL phase III study to integrate biomarker-driven identification of eligible ABC patients. Although the ROBUST trial did not meet the primary end point of PFS in all patients, the safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
Do optic neuritis patients report their visual impairment more frequently upon awakening?
Eslami, Mohammad‐Javad , Etemadifar, Masoud , Khalili, Mohammad Reza , Faraidan-Esfahani, Mahboobeh, Jahanbani‐Ardakani, Hamidreza , Ghorbani, Sara, Ghorbani, Sarah , Abtahi, Seyed-Hossein

Mayo Clinic

International Journal of Neuroscience | February 23, 2021 | Volume: 132 | Issue: 12 | Pages: 1261-1263

10.1080/00207454.2021.1879062 | PMID 33618604 Get It

A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities
Tulledge‐Scheitel, Sidna M. , Bell, Sarah, Larsen, Jennifer J., Bierle, Dennis M. , Moehnke, Darcie E. , Borgen, Molly J. Destro, Springer, Donna J., Reinschmidt, Karen J. , Baumbach, Lori J., Matoush, Jennifer A., Heyliger, Alexander , Hanson, Sara N. , Ganesh, Ravindra , Tulledge-Scheitel, Sidna, Bell, Sarah J. , Takahashi, Paul, Destro Borgen, Molly J, Razonable, Raymund R , Ganesh, Ravindra , Takahashi, Paul Y. , Razonable, Raymund R.

Mayo Clinic

Journal of the American Geriatrics Society | February 22, 2021 | Volume: 69 | Issue: 4 | Pages: 868-873

10.1111/jgs.17090 | PMID 33619724 Get It

Abstract Background Residents of nursing homes and long‐term care facilities are at increased risk for severe coronavirus disease‐19 (COVID‐19) but may not be able to access monoclonal antibody therapies offered at outpatient infusion centers due to frailty and logistical issues. We describe a mobile monoclonal antibody infusion program for patients with COVID‐19 in skilled nursing facilities and provide descriptive data on its outcomes. Design Retrospective cohort study. Setting Collaboration between Mayo Clinic and skilled nursing facilities in Southeast Minnesota was developed to administer anti‐spike monoclonal antibodies under the FDA Emergency Use Authorization. Participants Seventy five residents of skilled nursing facilities at high risk of COVID‐19 complications. Exposure Emergency use treatment with bamlanivimab and casirivimab–imdevimab. Measurements Hospitalization and medically attended visits. Results The mobile infusion unit, staffed by Mayo Clinic Infusion Therapy registered nurses and supported by the skilled nursing facility staff, infused anti‐spike monoclonal antibodies to 45 of 75 patients (average age, 77.8 years) in December 2020. The infusions occurred at an average of 4.3 days after COVID‐19 diagnosis. Fourteen days after infusion, there were no deaths, two emergency department visits, and three hospitalizations, for a combined event rate of 11.1%. There was one reported adverse event. Conclusion The implementation of a mobile infusion unit embedded in a collaborative process resulted in rapid infusion of monoclonal antibodies to high‐risk COVID‐19 patients in skilled nursing facilities, who would otherwise be unable to access the novel therapies. The therapies were well tolerated and appear beneficial. Further study is warranted to explore the scalability and efficacy of this program.